Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. 1989

T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.

The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen. A pneumonia model was successfully produced by inhalation of a virulent strain of Pseudomonas aeruginosa in guinea pigs immunosuppressed with cortisone acetate. One or 4 days after infection, the animals were treated orally with the fixed daily doses of ofloxacin either once a day or thrice a day for 3 consecutive days. Ofloxacin given thrice a day eliminated the organisms from the lung more efficiently than the equivalent total doses injected once a day in both series of treatment, starting 1 or 4 days after infection. The superiority of the triple dosing in chemotherapeutic efficacy of ofloxacin was found to be attributable at least to the longer retention of its pulmonary levels exceeding the antibiotic concentrations.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015242 Ofloxacin A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. DL-8280,DR-3355,Hoe-280,ORF-28489,Ofloxacin Hydrochloride,Ofloxacine,Ru-43280,Tarivid,DL 8280,DL8280,DR 3355,DR3355,Hoe 280,Hoe280,ORF 28489,ORF28489,Ru 43280,Ru43280

Related Publications

T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
March 1986, Antimicrobial agents and chemotherapy,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
May 1995, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1983, Reviews of infectious diseases,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
November 1993, The Journal of infectious diseases,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1979, Archives roumaines de pathologie experimentales et de microbiologie,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1956, Rivista italiana d'igiene,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
February 2017, Microbiology and immunology,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1987, Infection,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1987, Infection,
T Otani, and R Nakajima, and S Hashimoto, and Y Iigo, and Y Ishida, and T Une, and Y Osada
January 1982, Microbiology and immunology,
Copied contents to your clipboard!